What patients taking Ozempic, Wegovy, Mounjaro, and other GLP-1 medications should know about their eye health.
GLP-1 medications have become increasingly popular for managing type 2 diabetes and supporting weight loss. However, a new safety update from the U.S. Food and Drug Administration (FDA), announced November 9, 2026, highlights a potential association between these medications and a rare but serious eye condition called Non-Arteritic Anterior Ischemic Optic Neuropathy (NAION).
The FDA is now requiring manufacturers of GLP-1 medications to include information about this potential risk in the Warnings and Precautions section of their drug labeling.
What Is NAION?
NAION, sometimes referred to as an "eye stroke," occurs when blood flow to the optic nerve is reduced, resulting in sudden damage to the nerve. It typically causes sudden, painless vision loss in one eye, which can be permanent.
Symptoms may include:
Sudden, painless vision loss in one eye, sometimes noticed upon waking.
Blurred or hazy vision.
Missing areas of vision or blind spots.
Changes in color perception.
Loss of central or peripheral vision.
NAION is a serious condition that requires prompt medical evaluation.
Which Medications Are Associated With This Potential Risk?
The FDA's updated safety communication applies to GLP-1 receptor agonist medications, including commonly prescribed medications such as:
Ozempic (semaglutide)
Wegovy (semaglutide)
Rybelsus (semaglutide)
Mounjaro (tirzepatide)
Zepbound (tirzepatide)
Trulicity (dulaglutide)
Victoza and Saxenda (liraglutide)
The FDA reviewed data from 126 clinical trials involving more than 134,000 patients. The analysis identified approximately 6.4 cases of NAION per 100,000 person-years among patients taking GLP-1 medications, compared with 3.8 cases per 100,000 person-years in comparison groups.
Although the overall risk remains rare, the findings prompted the FDA to require updated safety labeling.
Importantly, an association does not necessarily establish that these medications directly cause NAION. More research is needed to better understand the relationship.
Who May Be at Higher Risk?
NAION can occur in individuals with certain underlying health conditions and risk factors, including:
Diabetes.
High blood pressure.
Obstructive sleep apnea.
Smoking.
Anemia.
Kidney disease.
Because many patients taking GLP-1 medications may already have some of these risk factors, it is especially important to monitor overall health and maintain regular eye examinations.
What Should Patients Do?
If you are currently taking a GLP-1 medication, there is no need to panic or independently discontinue your prescription. The benefits of these medications may be significant, and any concerns about continuing treatment should be discussed with your prescribing healthcare provider.
However, sudden, painless vision changes in either eye should never be ignored. If you experience sudden vision loss, new blind spots, or other unexpected visual disturbances, seek immediate medical attention and an urgent ophthalmologic evaluation.
Why Routine Eye Exams Matter
Your eyes can provide important information about your overall health. Comprehensive eye examinations allow your optometrist to evaluate the optic nerve, assess for changes in ocular health, and identify potential risk factors that may affect your vision.
As the use of GLP-1 medications continues to grow, communication between patients, optometrists, and prescribing physicians is increasingly important.
If you take Ozempic, Wegovy, Mounjaro, or another GLP-1 medication, let us know during your next eye examination. We are here to help you stay informed, protect your vision, and maintain your long-term eye health.
Your vision is important. Stay informed, stay proactive, and don't ignore sudden changes in your eyesight.
Source: U.S. Food and Drug Administration (FDA), November 9, 2026. FDA Safety Communication: GLP-1 Medications and Potential Risk of NAION.